Loading patent…
OwnerSheena Loosmore, Gavin Zealey +2inventors
InventorsSheena Loosmore, Gavin Zealey, Reza Yacoob, Michel Klein
Estimating the term…
A protein expression levels from Bordetella strains, particularly Bordetella pertussis, are altered by genetic modification to a natural Bordetella strain whereby one or more of the natural genes, particularly including the TOX, FHA, CYA and PRN genes, is deleted from the genome of the natural strain and one or more of the natural genes or a genetic mutation thereof, particularly a genetically-detoxified TOX* gene, or a hybrid gene, is inserted into the genome of the natural strain to provide at least two copies of one or more of the natural genes or genetic mutation thereof or hybrid gene, singly or in tandem. The altered genotype Bordetella strain is useful in producing whole-cell or defined component vaccines against Bordetella, particularly whooping cough, which may be employed in combination with other vaccines.
A genetically-modified Bordetella strain having one or more of the natural Bordetella genes deleted from the genome and one or more of the natural Bordetella genes or a genetic mutation of the natural Bordetella gene, or a hybrid Bordetella gene comprising a Bordetella gene under the regulation of a promoter of another Bordetella gene, inserted into the genome to provide at least two copies of one or more of the natural Bordetella genes or genetic mutation of the natural Bordetella gene, or hybrid Bordetella gene, in the genome, singly or in tandem, to effect increased expression levels of proteins encoded by Bordetella genes present in said genetically-modified Bordetella strain in comparison to the natural unmodified Bordetella strain.
A Bordetella strain having integrated into the genome thereof at least two copies (tandem or non-tandem) of a hybrid Bordetella gene comprising a Bordetella gene under the regulation of a promoter of another Bordetella gene.
Dependencies are inferred from the claim text.